Centocor Remicade Two-Year X-Ray Progression Data To Be Ready For Cmte.
Executive Summary
Centocor will have two-year x-ray data on Remicade in the prevention of rheumatoid arthritis progression available for review at the upcoming meeting of FDA's Arthritis Drugs Advisory Committee.